Yunnan Botanee Bio-Technology Group Co.LTD Share Price

Equities

300957

CNE100004G74

Personal Products

End-of-day quote Shenzhen S.E. 23:00:00 25/04/2024 BST 5-day change 1st Jan Change
55.35 CNY -3.76% Intraday chart for Yunnan Botanee Bio-Technology Group Co.LTD 0.00% -18.81%

Financials

Sales 2024 * 7.27B 1B 80.37B Sales 2025 * 9.31B 1.28B 103B Capitalization 23.28B 3.21B 257B
Net income 2024 * 1.06B 146M 11.73B Net income 2025 * 1.85B 255M 20.41B EV / Sales 2024 * 2.7 x
Net cash position 2024 * 3.62B 499M 39.97B Net cash position 2025 * 4.48B 618M 49.52B EV / Sales 2025 * 2.02 x
P/E ratio 2024 *
15.7 x
P/E ratio 2025 *
12.7 x
Employees 3,852
Yield 2024 *
1.41%
Yield 2025 *
2.17%
Free-Float 27.75%
More Fundamentals * Assessed data
Dynamic Chart
Yunnan Botanee Bio-Technology Group Co.LTD Proposes Final Dividend for 2023 CI
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Yunnan Botanee Bio-Technology Group Co.LTD's Equity Buyback Plan announced on August 30, 2023. CI
Certain A Shares of Yunnan Botanee Bio-Technology Group Co.LTD are subject to a Lock-Up Agreement Ending on 25-MAR-2024. CI
Weimai Medical Technology Co., Ltd. announced that it has received funding from CDH Investment Management Company Limited, Yunnan Botanee Bio-Technology Group Co.LTD CI
Weimai Qingtong Medical Technology Co., Ltd. announced that it has received funding from CDH Investment Management Company Limited, Changzhou Lizhong Investment Management Co., Ltd., Yunnan Botanee Bio-Technology Group Co.LTD, Guangdong Evergreen Conglomerate Co., Ltd. CI
Tranche Update on Yunnan Botanee Bio-Technology Group Co.LTD's Equity Buyback Plan announced on August 30, 2023. CI
In China's slowing beauty market, big brand discounts won't cut it RE
Shanghai Weimu Medical Technology Co., Ltd. announced that it has received CNY 100 million in funding from Yunnan Botanee Bio-Technology Group Co.LTD, Huajin Avenue Investment Co., Ltd., SHAREWIN Equity Investment and Management Co., Ltd., Shanghai CS Capital Co., Ltd, Sinvo Capital Holdings Co., Ltd., Investment Arm, IDG Capital Partners Co., Ltd. CI
Jefferies Adjusts Yunnan Botanee Bio-Technology’s Price Target to 87 Yuan From 105 Yuan, Keeps at Hold MT
Yunnan Botanee Bio-Technology Group Co.LTD Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Yunnan Botanee Bio-Technology Group Co.LTD announces an Increase in Equity Buyback. CI
Weimai Medical Technology Co., Ltd. announced that it has received funding from Yunnan Botanee Bio-Technology Group Co.LTD CI
Yunnan Botanee Bio-Technology Group Co.LTD announces an Equity Buyback for CNY 200 million worth of its shares. CI
More news
1 day-3.76%
Current month-7.70%
1 month-9.68%
3 months-9.91%
6 months-23.42%
Current year-18.81%
More quotes
1 week
53.44
Extreme 53.44
58.80
1 month
53.44
Extreme 53.44
62.05
Current year
51.50
Extreme 51.5
72.00
1 year
51.50
Extreme 51.5
116.00
3 years
51.50
Extreme 51.5
289.35
5 years
51.50
Extreme 51.5
289.35
10 years
51.50
Extreme 51.5
289.35
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 31/05/14
Director of Finance/CFO 42 30/11/16
Director/Board Member 45 30/06/12
Members of the board TitleAgeSince
Director/Board Member 56 30/09/13
Chief Executive Officer 61 31/05/14
Director/Board Member 60 28/02/19
More insiders
Date Price Change Volume
26/04/24 55.35 -3.76% 8,286,093
25/04/24 57.51 -0.95% 2,296,200
24/04/24 58.06 -0.53% 2,535,829
23/04/24 58.37 +3.99% 3,692,728
22/04/24 56.13 +1.41% 2,431,658

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes
Yunnan Botanee Bio-Technology Group Co LTD is a Chinese company mainly engaged in the production of cosmetics. The Company adopts a sales model based on offline channel sales and online channel sales as the leading factor. The Company's products mainly include creams, skin care lotions, facial masks, essences, lotions and other skin care products and make-up products such as isolation creams, blemish balm (BB) creams, and makeup removers. The Company is also engaged in the research and development, production and sales of skin care-related medical device products, mainly including hyaluronic acid repairing biofilm, hyaluronic acid repairing dressings, mainly used for the protection of skin with damaged barriers after minimally invasive surgery and care.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
55.35 CNY
Average target price
89.86 CNY
Spread / Average Target
+62.34%
Consensus
  1. Stock Market
  2. Equities
  3. 300957 Stock